Antibody Agents in Solid Organ Transplantation

Journal of Pharmacy Practice

Volumn 16, Issue 6, 2003, Pages 388-400

  Somerville, K Troy ^a  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

Antibody immunosuppressive agents; Induction immunosuppression; Transplantation

Indexed keywords

ADRENALIN; BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; DIPHENHYDRAMINE; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PARACETAMOL; POLYCLONAL ANTIBODY; STEROID; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANAPHYLAXIS; ARTHRALGIA; ASEPTIC MENINGITIS; CELLULITIS; CHILL; CLINICAL TRIAL; CYTOKINE RELEASE; CYTOKINE RELEASE SYNDROME; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG USE; DYSPNEA; FEVER; HEADACHE; HEART DISEASE; HUMAN; HYPERKALEMIA; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPOTENSION; INFECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LUNG EDEMA; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; MYALGIA; NAUSEA; ORGAN TRANSPLANTATION; PAIN; PERIPHERAL EDEMA; PHLEBITIS; RASH; REVIEW; RIGOR; RISK ASSESSMENT; SQUAMOUS CELL CARCINOMA; TACHYCARDIA; THORAX PAIN; THROMBOCYTOPENIA; TREMOR; VOMITING; WHEEZING; WOUND INFECTION;

EID: 1642577045     PISSN: 08971900     EISSN: None     Source Type: Journal    
DOI: 10.1177/0897190003259835     Document Type: Review

References (33)

1. Atgam [package insert]. Kalamazoo, Mich: Pharmacia and Upjohn Company; 2003.
2. Bock HA, Gallati H, Zurcher RM, et al. A randomized prospective trial of prophylactic immunosuppression with ATG-fresenius versus OKT3 after renal transplantation. Transplantation. 1995;59(6):830-840.
3. Cosimi AB, Wortis HH, Delmonico FL, Russell PS. Randomized clinical trial of antithymocyte globulin in cadaver renal allograft recipients: importance of T cell monitoring. Transplantation. 1976;80(2):155-163.
4. Orthoclone OKT3 [package insert]. Raritan, NJ: Ortho Biotech Products.
5. Jensen PB, Birkeland SA, Rohrp N, et al. Development of anti-OKT3 antibodies after OKT3 treatment. Scand J Urol Nephrol. 1996;30(3):227-230.
6. Broeders N, Wissing KM, Crusiaux A, et al. Mycophenolate mofetil, together with cyclosporin A, prevents anti-OKT3 antibody response in kidney transplant recipients. J Am Soc Nephrol. 1998;9(8):1521-1525.
7. Thistlewaite JR Jr, Stuart JK, Mayes JT, et al. Complications and monitoring of OKT3 therapy. Am J Kidney Dis. 1988;11(2):112-119.
8. Hooks MA, Wade CS, Millikan WJ Jr. Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation. Pharmacotherapy. 1991;11(1):26-37.
9. Alloway R, Kotb M, Hathaway DK, Gaber LW, Vera SR, Gaber AO. Randomized double-blind study of standard versus low-dose OKT3 induction therapy in renal allograft recipients. Am J Kidney Dis. 1993;22(1):36-43.
10. Flechner SM, Goldfarb DA, Fairchild R, et al. A randomized prospective trial of low-dose OKT3 induction therapy to prevent rejection and minimize side effects in recipients of kidney transplants. Transplantation. 2000;69(11):2374-2381.
11. Henry ML, Pelletier RP, Elkhammas EA, Bumgardner GL, Davies EA, Ferguson RM. A randomized prospective trial of OKT3 induction in the current immunosuppression era. Clin Transplant. 2001;15(6):410-414.
12. Kahana L, Narvarte J, Ackermann J, et al. OKT3 prophylaxis versus conventional drug therapy: single-center perspective, part of a multicenter trial. Am J Kidney Dis. 1989;14(5 suppl 2):5-9.
13. Norman DJ, Shield CF III, Barry J, et al. Early use of OKT3 monoclonal antibody in renal transplantation to prevent rejection. Am J Kidney Dis. 1988;11(2):107-110.
14. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med. 1985;313(6):337-342.
15. Norman DJ, Shield CF III, Barry JM, et al. Therapeutic use of OKT3 monoclonal antibody for acute renal allograft rejection. Nephron. 1987;46(suppl 1):41-47.
16. Vela C, Cristol JP, Chong G, et al. Antilymphocyte globulins versus OKT3 as prophylactic treatment in highly sensitized renal transplant recipients. Transplant Intl. 1994;7(suppl 1):S259-S262.
17. Thymoglobulin [package insert]. Fremont, Calif: SangStat Medical Corporation; 2002.
18. Revillard JP, Bonnefoy-Berard N, Preville X, et al. Immunopharmacology of Thymoglobulin. Graft. 1999;2(1 suppl):177-180.
19. Regan JF, Campbell K, Van Smith L, et al. Sensitization following Thymoglobulin and Atgam rejection therapy as determined with a rapid enzyme-linked immunosorbent assay. US Thymoglobulin Multi-Center Study Group. Transplant Immunol. 1999;7(2):115-121.
20. Campbell K, Smith L, Le H, et al. Thymoglobulin serum levels in renal transplant patients undergoing treatment for acute rejection. Paper presented at: 16th Annual Meeting of the American Society of Transplant Physicians; May 10-14, 1997; Chicago.
21. Peddi VR, Bryant M, Roy-Chaudhury P, Woodle ES, First MR. Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosing based on CD3+ lymphocyte counts in kidney and kidney-pancreas transplant recipients. Transplantation. 2002;73(9):1514-1518.
22. Krasinskas AM, Kreisel D, Acker MA, et al. CD3 monitoring of antithymocyte globulin therapy in thoracic organ transplantation. Transplantation. 2002;73(8):1339-1341.
23. Gaber AO, First MR, Tesi RJ, et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation. 1998;66(1):29-37.
24. Brennan DC, Flavin K, Lowell JA, et al. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation. 1999;67(7):1011-1018.
25. Smith LD, Somerville KT, Sundberg A, et al. Superior acute rejection prophylaxis of thymoglobulin compared to OKT3 in cadaveric and living-unrelated renal transplants. Paper presented at: American College of Clinical Pharmacy 2002 Annual Meeting; October 2002; Albuquerque, NM.
26. Lebranchu Y, Bridooux F, Buchler, et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant. 2002;2(1):48-56.
27. Brennan DC, Thymoglobulin Induction Study Group. Thymoglobulin versus Simulect for induction immunosuppression in cadaveric renal transplant recipients: expanded results from a prospective, randomized, multicenter trial [abstract]. Am J Transplant. 2003;5(3):438-439.
28. Wiseman LR, Faulds D. Daclizumab. A review of its use in the prevention of acute rejection in renal transplant recipients. Drugs. 1999;58:1029-1042.
29. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med. 1998;338(3):161-165.
30. Nashan B, Light S, Hardie IR, Lin A, Johnson JR. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation. 1999;67(1):110-115.
31. Bumgardner GL, Hardie I, Johnson RW, et al. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation. 2001;72(5):839-845.
32. Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation. 1999;67(2):276-284.
33. Brennan DC. A prospective, randomized, multi-center study of thymoglobulin compared to Simulect for induction immunosuppression: preliminary results. American Transplant Congress. Transplant 2002. Abstracts-on-disk. Abstract 398.